Keensight Capital, a private equity manager dedicated to pan-European Growth Buyout investments, has appointed Dr Uwe Gottschalk as an Operating Partner.
Gottschalk was most recently Chief Scientific Officer (CSO) of Lonza Group, the world’s largest company for biologics contract development and manufacturing, and Group Vice President at Sartorius Stedim Biotech, where he had global responsibility for bioseparation process technologies.
Gottschalk will be joining Keensight Capital’s team of international Operating Partners. This network, spanning Europe, Asia, and the US, connects eminent professionals in the Technology and Healthcare industries.
